AKRO - NASDAQ

Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKROยทNASDAQ

$54.65

+0.0000%
HealthcareBiotechnology

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$4.50B
EPS-3.7500
P/E Ratio-14.57
Earnings Date02/27/2026
Akero Therapeutics, Inc.

Akero Therapeutics, Inc. Fair Value Envelope

AKRO ยท NASDAQ

Our analysis suggests that AKRO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $54.65, this represents a potential HIDDEN relative to our calculated worth for Akero Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $54.65

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$198.5M
+ Cash & Equivalents$340.2M
Firm Value$141.8M
- Debt$36.5M
Equity Value$105.3M
/ Shares Outstanding82,316,179B
DCF Value$1
OVERVALUED BY 98%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$115.1M
-$57.5M
-$28.8M
-$14.4M
-$7.2M
-$3.6M
-$1.8M
-$898.9K
-$449.4K
-$224.7K
Maintenance CapEx
-$99.9K
-$50.0K
-$25.0K
-$12.5K
-$6.2K
-$3.1K
-$1.6K
-$780
-$390
-$195
Owner Earnings
-$115.2M
-$57.6M
-$28.8M
-$14.4M
-$7.2M
-$3.6M
-$1.8M
-$899.6K
-$449.8K
-$224.9K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$106.6M
-$49.4M
-$22.9M
-$10.6M
-$4.9M
-$2.3M
-$1.0M
-$486.0K
-$225.0K
-$104.2K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your AKRO research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.